FILTER

Refine your search with the following facets to narrow down your results.

6 Current news of Endotis Pharma

Endotis Pharma reports successful completion of the neutralization study of the anticoagulant EP217609 by avidin

17-Nov-2010 - Endotis Pharma announced that it has successfully completed the first study assessing in healthy subjects the neutralization of the anticoagulant EP217609 by its specific antidote avidin. EP217609 and avidin were well tolerated in the 36 healthy subjects enrolled in this study. A single ...

cardiothoracic surgery clinical trials Neutralization +1

Endotis Pharma presents Phase I clinical trial results for a first-in-class synthetic parenteral neutralizable anticoagulant

09-Jul-2010 - Endotis Pharma announced that Phase I clinical trial results for EP217609 were presented at the 21st International Congress on Thrombosis (ICT) in Milan, Italy. EP217609 is a first-in-class synthetic, parenteral anticoagulant which can be neutralized by a specific antidote, avidin. EP217609 has a ...

cardiothoracic surgery clinical trials Italy +4

Endotis Pharma presents data on the neutralizable anticoagulant EP217609 in an extracorporeal circulation model

04-Jun-2010 - Endotis Pharma presented that initial results on the neutralizable anticoagulant EP217609 in a canine model of extracorporeal circulation (ECC) at the French Society of Thoracic and Cardiovascular Surgery's 63th annual meeting in Tours, France. Both EP217609 and its specific antidote avidin were ...

cardiovascular surgery clinical trials Neutralization

Endotis reports the successful completion of Phase I clinical trials of neutralizable anticoagulant EP217609 and antidote avidin

03-May-2010 - Endotis Pharma announced that the neutralizable anticoagulant EP217609 and its specific antidote avidin have successfully completed their respective first-in-man Phase I clinical trials. EP217609 is a first-in-class synthetic, parenteral anticoagulant which can be neutralized with a specific ...

clinical trials pharmacokinetics

Endotis Pharma forms a strategic alliance with Catalent Pharma Solutions for the development of synthetic oligosaccharides

02-Nov-2009 - Endotis Pharma announced the formation of a strategic alliance with Catalent Pharma Solutions (a worldwide leader in pharmaceutical technologies and services). The two companies will collaborate exclusively to develop certain oral formulations of small-glyco drugs and are now focusing on the ...

clinical trials Formation inhibitors +1

Organon signs an exclusive, worldwide licence agreement on advanced antithrombotic compounds with Endotis Pharma

02-Nov-2007 - Organon, the human healthcare business unit of Akzo Nobel, announced that it has signed an exclusive, worldwide license agreement with Endotis Pharma concerning the development and commercialization of several antithrombotic compounds. Endotis is a specialty pharma company dedicated to the ...

Akzo Nobel clinical trials license agreements +3